Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.35 |
| ▸ | CHRNE | Q04844 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3793136 | 0.83 | GABRA1 (0.46) | LIPGENPP2KDM4EALDH1A1GABRA1 | |
| SCHEMBL3790530 | 0.80 | LIPG (0.50) | LIPGGABRA1GABRB2 | |
| SCHEMBL15390567 | 0.79 | APOBEC3G (0.44) | PDCD1CD274CHRNEAPOBEC3GKDM4E | |
| SCHEMBL29377890 | 0.78 | LIPG (0.55) | LIPGPDCD1CD274ENPP2APOBEC3G | |
| SCHEMBL8530 | 0.78 | LIPG (0.55) | LIPGPDCD1CD274ENPP2APOBEC3G | |
| SCHEMBL3786328 | 0.77 | LIPG (0.61) | LIPG | |
| SCHEMBL5840438 | 0.77 | PDCD1 (0.52) | LIPGPDCD1CD274ENPP2APOBEC3G | |
| SCHEMBL3783913 | 0.77 | LIPG (0.41) | LIPGPDCD1CD274ENPP2APOBEC3G | |
| SCHEMBL29955362 | 0.77 | LIPG (0.41) | LIPGPDCD1CD274ENPP2APOBEC3G | |
| SCHEMBL22717297 | 0.76 | ENPP2 (0.44) | LIPGPDCD1CD274ENPP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | LIPG 3010/4885PDCD1 465/4885CD274 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.